Neil W. Kowall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Neil W. Kowall has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ann Carolyn McKee
Boston University Alzheimer's Disease Research Center and Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA
3 shared publications - Alpaslan Dedeoglu
Department of Veterans Affairs, VA Boston Healthcare System, Boston, MA 02130, USA
1 shared publication - Andrew E. Budson
Neurology Service, Veterans Affairs Boston Healthcare System, United States
1 shared publication - Angela L. Jefferson
Vanderbilt Memory and Alzheimer's Center Vanderbilt University School of Medicine Nashville Tennessee USA
1 shared publication Boston University Alzheimer’s Disease Research Center
1 shared publicationBruce G. Jenkins
Radiology, MGH and Harvard Medical School, Boston, MA 02114, USA
1 shared publication
Latest Publications
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S15)
Proteome Analysis in Plasma and Brain Reveals a Novel Plasma Biomarker Linked to Antemortem Cognitive Impairment and Postmortem Neuropathological Traits for Alzheimer Disease
Background: Identification of blood‐based biomarkers that are indicative of Alzheimer’s disease (AD) pathology may help with early detection.Methods: We generated proteome data for ∼7,000 proteins in both antemortem plasma and postmortem brain tissue from 103 participants of the Boston University Alzheimer’s Disease Research Center. All participants completed comprehensive neuropsychological evaluations and dementia severity was measured by global cognitive dementia rating (CDR) scores. A pathological AD diagnosis was established using NIA Reagan criteria. We conducted association tests with dementia (i.e., CDR ≥1 for dementia, CDR plasma = 0.005, Pbrain = 0.001) and dementia (Pplasma = 0.01, Pbrain = 9×10−5). ACES and AURKB levels in plasma and brain were significantly associated with dementia (P<0.05). Levels of these. Increased MMP‐8 level in plasma was associated with decreased animals (P = 0.03) and scores (P = 0.04), which both assess verbal fluency. Dementia and pathologically confirmed AD were associated with lower AURKB and elevated ACES levels in plasma. Decreased plasma ACES level was associated with executive function (TrailsB: P = 0.01) and language (Boston Naming Test: P = 0.02) impairment, and the reduced plasma AURKB level was associated with memory impairment (Logical Memory Immediate Recall score: P = 0.03).Conclusion: MMP‐8, a neutrophil collagenase and member of the matrix metalloproteinase family, is a potential blood‐based biomarker for dementia and underlying AD pathology and is associated predominantly with impaired verbal fluency.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S15)
Open AccessProteome Analysis in Plasma and Brain Reveals a Novel Plasma Biomarker Linked to Antemortem Cognitive Impairment and Postmortem Neuropathological Traits for Alzheimer Disease
Background: Identification of blood‐based biomarkers that are indicative of Alzheimer’s disease (AD) pathology may help with early detection.Methods: We generated proteome data for ∼7,000 proteins in both antemortem plasma and postmortem brain tissue from 103 participants of the Boston University Alzheimer’s Disease Research Center. All participants completed comprehensive neuropsychological evaluations and dementia severity was measured by global cognitive dementia rating (CDR) scores. A pathological AD diagnosis was established using NIA Reagan criteria. We conducted association tests with dementia (i.e., CDR ≥1 for dementia, CDR plasma = 0.005, Pbrain = 0.001) and dementia (Pplasma = 0.01, Pbrain = 9×10−5). ACES and AURKB levels in plasma and brain were significantly associated with dementia (P<0.05). Levels of these. Increased MMP‐8 level in plasma was associated with decreased animals (P = 0.03) and scores (P = 0.04), which both assess verbal fluency. Dementia and pathologically confirmed AD were associated with lower AURKB and elevated ACES levels in plasma. Decreased plasma ACES level was associated with executive function (TrailsB: P = 0.01) and language (Boston Naming Test: P = 0.02) impairment, and the reduced plasma AURKB level was associated with memory impairment (Logical Memory Immediate Recall score: P = 0.03).Conclusion: MMP‐8, a neutrophil collagenase and member of the matrix metalloproteinase family, is a potential blood‐based biomarker for dementia and underlying AD pathology and is associated predominantly with impaired verbal fluency.
- Open Access
- 1 September 2021
- Published by Elsevier in Progress in Neurobiology
- Vol. 204, 102110
Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntington’s disease
- 1 September 2021
- Published by Elsevier in Progress in Neurobiology
- Vol. 204, 102110
Open AccessDysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntington’s disease
- 1 April 2014
- Published by Elsevier in Neuroscience Letters
- Vol. 566, 286-291
7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis
- 1 April 2014
- Published by Elsevier in Neuroscience Letters
- Vol. 566, 286-291
7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis
- 14 March 2008
- Published by Optica Publishing Group in Optics Letters
- Vol. 33 (6) , 624-626
Scattering differentiates Alzheimer disease in vitro
The molecular bases of Alzheimer disease and related neurodegenerative disorders are becoming better understood, but the means for definitive diagnosis and monitoring in vivo remain lacking. Near-infrared optical spectroscopy offers a potential solution. We acquired transmission and reflectance spectra of thin brain tissue slabs, from which we calculated wavelength-dependent absorption and reduced scattering coefficients from . The reduced scattering coefficients in the near infrared clearly differentiated Alzheimer from control specimens. Diffuse reflectance spectra of gross brain tissue in vitro confirmed this observation. These results suggest a means for diagnosing and monitoring Alzheimer disease in vivo, using near-infrared optical spectroscopy.- 14 March 2008
- Published by Optica Publishing Group in Optics Letters
- Vol. 33 (6) , 624-626
Scattering differentiates Alzheimer disease in vitro
The molecular bases of Alzheimer disease and related neurodegenerative disorders are becoming better understood, but the means for definitive diagnosis and monitoring in vivo remain lacking. Near-infrared optical spectroscopy offers a potential solution. We acquired transmission and reflectance spectra of thin brain tissue slabs, from which we calculated wavelength-dependent absorption and reduced scattering coefficients from . The reduced scattering coefficients in the near infrared clearly differentiated Alzheimer from control specimens. Diffuse reflectance spectra of gross brain tissue in vitro confirmed this observation. These results suggest a means for diagnosing and monitoring Alzheimer disease in vivo, using near-infrared optical spectroscopy.- Open Access
- 1 March 2008
- Published by Wiley in The FASEB Journal
- Vol. 22 (S1) , 707.7
Dense neurofibrillary degeneration of the posterior cortex, BA 19/37, in a cognitively normal monozygotic twin at high risk for Alzheimer's disease
We previously reported that 50% of cognitively intact elderly have dense neurofibrillary degeneration in Brodmann area (BA) 19/37. We now report the finding of focal tau pathology in the posterior cortex of a cognitively intact identical twin at high risk for AD. A male Caucasian chemical engineer developed AD symptoms at age 60, first manifest as the inability to read maps, followed by progressive loss of memory and intellect over 16 years until his death at age 76. Post‐mortem exam confirmed severe AD (NIA‐Reagan: high, CERAD plaque: frequent, Braak: VI). His identical twin, also a chemical engineer with an identical education, died at 79 years from prostate cancer. At the time of his death, he was cognitively intact, except for slight loss of his navigational skills. Post‐mortem exam revealed sparse neuritic plaques and entorhinal and transentorhinal NFTs (NIA‐Reagan: low, CERAD: sparse, Braak: II). Despite the mild non‐diagnostic AD changes, there were dense NFTs, neuropil threads and tau immunoreactive neuritic plaques in the posterior cortex, BA 19/37. The finding of dense BA 19/37 pathology in this monozygotic twin, at high risk for the development of AD, but in the preclinical stages of AD at the time of his death, further confirms the early neurofibrillary degeneration of the posterior cortex in some individuals prior to the development of AD. Supported by NIA P30 AG13846, and by the Dept of Veteran's Affairs.
- 1 March 2008
- Published by Wiley in The FASEB Journal
- Vol. 22 (S1) , 707.7
Open AccessDense neurofibrillary degeneration of the posterior cortex, BA 19/37, in a cognitively normal monozygotic twin at high risk for Alzheimer's disease
We previously reported that 50% of cognitively intact elderly have dense neurofibrillary degeneration in Brodmann area (BA) 19/37. We now report the finding of focal tau pathology in the posterior cortex of a cognitively intact identical twin at high risk for AD. A male Caucasian chemical engineer developed AD symptoms at age 60, first manifest as the inability to read maps, followed by progressive loss of memory and intellect over 16 years until his death at age 76. Post‐mortem exam confirmed severe AD (NIA‐Reagan: high, CERAD plaque: frequent, Braak: VI). His identical twin, also a chemical engineer with an identical education, died at 79 years from prostate cancer. At the time of his death, he was cognitively intact, except for slight loss of his navigational skills. Post‐mortem exam revealed sparse neuritic plaques and entorhinal and transentorhinal NFTs (NIA‐Reagan: low, CERAD: sparse, Braak: II). Despite the mild non‐diagnostic AD changes, there were dense NFTs, neuropil threads and tau immunoreactive neuritic plaques in the posterior cortex, BA 19/37. The finding of dense BA 19/37 pathology in this monozygotic twin, at high risk for the development of AD, but in the preclinical stages of AD at the time of his death, further confirms the early neurofibrillary degeneration of the posterior cortex in some individuals prior to the development of AD. Supported by NIA P30 AG13846, and by the Dept of Veteran's Affairs.
- 1 January 1999
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 13, S11-16
Alzheimer Disease 1999
- 1 January 1999
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 13, S11-16
Alzheimer Disease 1999